Alamar Biosciences, Inc. (NASDAQ:ALMR - Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 75,508 shares of the business's stock in a transaction on Monday, October 19th. The shares were sold at an average price of $26.34, for a total transaction of $1,988,880.72. Following the sale, the insider directly owned 180,808 shares in the company, valued at approximately $4,762,482.72. This trade represents a 29.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):
- On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
- On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.02, for a total value of $3,674.72.
- On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total value of $4,812,181.01.
Alamar Biosciences Trading Up 11.7%
Shares of ALMR stock opened at $31.45 on Thursday. The stock has a market capitalization of $2.18 billion and a P/E ratio of -16.05. Alamar Biosciences, Inc. has a 1-year low of $18.84 and a 1-year high of $39.61. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. The company's fifty day simple moving average is $30.86.
Alamar Biosciences (NASDAQ:ALMR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.14. The business had revenue of $29.43 million during the quarter. On average, sell-side analysts predict that Alamar Biosciences, Inc. will post -1.22 EPS for the current year.
Hedge Funds Weigh In On Alamar Biosciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new stake in Alamar Biosciences in the second quarter valued at approximately $283,000. State Street Corp bought a new stake in Alamar Biosciences in the second quarter worth approximately $3,930,000. Wellington Management Group LLP acquired a new position in shares of Alamar Biosciences during the 2nd quarter worth $12,407,000. Finally, Braidwell LP acquired a new position in shares of Alamar Biosciences during the 2nd quarter worth $29,365,000.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. Stifel Nicolaus upped their target price on Alamar Biosciences from $28.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. raised their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the stock an "overweight" rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Alamar Biosciences from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, October 8th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.80.
Check Out Our Latest Research Report on Alamar Biosciences
About Alamar Biosciences
(
Get Free Report)
Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.
Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
